



01-12-06

AF/1646
ZMWExpress Mail No.: EV 475 142 167 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Application of: Ish-Horowicz *et al.*

Confirmation No.: 8177

Serial No.: 09/783,931

Art Unit: 1646

Filed: February 15, 2001

Examiner: Claire M. Kaufman

For: ANTIBODIES TO VERTEBRATE DELTA
PROTEINS AND FRAGMENTS

Attorney Docket No: 7326-122

AMENDMENT FEE TRANSMITTAL SHEETCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

Please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: January 10, 2006Adriane M. Antler
Adriane M. Antler32,605
(Reg. No.)

By:

William J. Thoman
William J. Thoman40,203
(Reg. No.)**JONES DAY**222 East 41st Street

New York, New York 10017

(212) 326-3939



Express Mail No. EV 475 142 167 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ish-Horowicz *et al.*

Confirmation No.: 8177

Serial No.: 09/783,931

Art Unit: 1646

Filed: February 15, 2001

Examiner: Claire M. Kaufman

For: ANTIBODIES TO VERTEBRATE DELTA
PROTEINS AND FRAGMENTS

Attorney Docket No: 7326-122

AMENDMENT UNDER 37 C.F.R. § 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action, dated November 10, 2005, please enter the following amendments and consider the remarks made below in connection with the above-identified patent application. Submitted concurrently herewith are (a) an Amendment Fee Transmittal Sheet; (b) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and (c) a third substitute Sequence Listing in paper and computer-readable forms.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 20 of this paper.